论文部分内容阅读
目的观察通心络胶囊结合西医常规疗法对冠心病患者血清超敏C反应蛋白(hs-CRP)的影响。方法将126例冠心病患者随机分为治疗组和对照组(各63例),对照组采用西医常规疗法,治疗组在此基础上加用通心络胶囊;两组疗程均为6周,观察临床疗效及治疗后hs-CRP水平变化情况。结果治疗组、对照组总有效率分别为79.4%、63.5%;组间临床疗效比较,差异有统计学意义(P<0.05)。两组治疗后hs-CRP均明显降低(P<0.05);组间治疗后比较,差异有统计学意义(P<0.05)。结论通心络胶囊结合西医常规疗法治疗冠心病,可抑制炎症反应,提高临床疗效。
Objective To observe the effect of Tongxinluo capsule combined with routine western medicine on serum hs-CRP in patients with coronary heart disease. Methods 126 cases of coronary heart disease were randomly divided into treatment group and control group (63 cases each). The control group was treated with conventional western medicine. The treatment group was given Tongxinluo capsule on the basis of the above. The two groups were treated for 6 weeks. Clinical efficacy and hs-CRP levels after treatment changes. Results The total effective rates of the treatment group and the control group were 79.4% and 63.5% respectively. There was significant difference between the two groups in clinical efficacy (P <0.05). The hs-CRP levels of both groups were significantly decreased after treatment (P <0.05). There was significant difference between the two groups after treatment (P <0.05). Conclusion Tongxinluo capsule combined with conventional Western medicine treatment of coronary heart disease can inhibit the inflammatory response and improve clinical efficacy.